The goal of Histogenics (NasdaqGM: HSGX) is to become a leading regenerative medicine company developing, marketing and commercializing products in the musculoskeletal segment of the marketplace. The company plans to build its core technology platform as well as expand its clinical products’ therapeutic applications to develop new and innovative solutions. Histogenics leverages a combination of the latest advances in molecular biology and proprietary materials sciences to create products designed to help improve patient outcomes. The company’s regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. The company’s first product candidate, NeoCart, leverages its platform to provide an innovative treatment in the orthopaedic space, specifically cartilage damage in the knee. NeoCart is currently enrolling a Phase 3 clinical trial in the United States under a Special Protocol Assessment (SPA).

Histogenics had its initial public offering December 3, 2014.

Related News
Histogenics Corporation to Participate in Upcoming Scientific and Investor Conferences
WALTHAM, Mass., October 1, 2015 /GLOBE NEWSWIRE/ – Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be participating in four upcoming conferences. Read Full Release
Boston Millennia Portfolio Company, Histogenics, Completes Successful IPO
Millennia Portfolio Company, Histogenics, a regenerative medicine company, today announced the pricing of its underwritten initial public offering of 5,909,091 shares of its common stock at a price to the public of $11.00 per share. Read Full Release